Gary J Nabel

Washington, DC, United States of America

Gary J Nabel

USPTO Granted Patents = 108 

 

 

Average Co-Inventor Count = 3.8

ph-index = 21

Forward Citations = 4,211(Granted Patents)

Forward Citations (Not Self Cited) = 4,102(Dec 10, 2025)


Inventors with similar research interests:


Location History:

  • Newton, MA (US) (1988)
  • Ann Arbor, MI (US) (1994 - 2007)
  • Bethesda, MD (US) (2019)
  • Cambridge, MA (US) (1985 - 2024)
  • Washington, DC (US) (2001 - 2024)
  • Chestnut Hill, MA (US) (2018 - 2024)
  • Bridgewater, NJ (US) (2021 - 2024)

Company Filing History:

goldMedal48 out of 3,439 
 
The United States of America, As Represented by the Secretary, Department of Health and Human Services
 patents
silverMedal32 out of 3,371 
 
University of Michigan
 patents
bronzeMedal16 out of 1,451 
 
Sanofi
 patents
48 out of 389 
 
Genetics Institute, Inc.
 patents
58 out of 16,076 
 
USA As Represented by Secretary of the Navy
 patents
68 out of 1,207 
 
Dana-farber-cancer Institute Inc.
 patents
74 out of 2,100 
 
University of Washington
 patents
82 out of 531 
 
Glaxosmithkline Biologicals Sa
 patents
92 out of 68 
 
International Aids Vaccine Initiative
 patents
102 out of 1,187 
 
The Scripps Research Institute
 patents
111 out of 64 
 
Vical Incorporated
 patents
121 out of 88 
 
Genvec, Inc.
 patents
131 out of 1 
 
Genvex, Inc.
 patent
141 out of 2,538 
 
Warner-lambert Company
 patents
151 out of 1 
 
Sabin Vaccine Institute
 patent
161 out of 2,008 
 
Duke University
 patents
171 out of 115 
 
Janssen Vaccines & Prevention B.v.
 patents
183 out of 832,718 
Other
 patents
where one patent can have more than one assignee

Years Active: 1985-2025

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Virus-Like Particles
Chikungunya Virus
Epstein-Barr Virus
Hiv Neutralizing Antibodies
Trispecific Binding Proteins
Filovirus Vaccines
Ferritin Proteins
Bivalent Binding Proteins
Nucleic Acid Molecules
Immune Response Induction
Antigenic Polypeptides
Adenoviral Vector Vaccines
108 patents (USPTO):Explore Patents

Certainly! Here is an article about inventor Gary J Nabel:

Title: Innovator Spotlight: Gary J Nabel - Pioneering Vaccines and Ferritin Proteins

Introduction:

Gary J Nabel, a distinguished inventor, has made significant contributions in the field of vaccines and protein technology. With an impressive portfolio of 96 patents, Nabel's work has revolutionized preventative medicine. Based in Washington, DC, Nabel's innovative spirit and dedication to scientific advancement have led to groundbreaking discoveries.

Latest Patents:

1. Chimpanzee adenoviral vector-based filovirus vaccines: Nabel's invention provides vaccines that induce an immune response and protect against filovirus infections in humans. By using chimpanzee adenoviral vectors expressing filovirus proteins, the vaccine offers protection against strains of Ebolavirus and Marburg virus.

2. Ferritin proteins: Nabel's ferritin proteins, comprising mutations and immune-stimulatory moieties, have opened new possibilities in eliciting antibodies and developing antigenic responses against various pathogens.

Career Highlights:

Nabel has notably collaborated with esteemed institutions such as the University of Michigan and The United States of America, represented by the Department of Health and Human Services. His work reflects a dedication to public health and a commitment to advancing medical science for the betterment of society.

Collaborations:

Throughout his career, Nabel has collaborated with accomplished professionals such as Zhi-yong Yang and Elizabeth G Nabel. These collaborations have played a vital role in advancing his research and bringing innovative solutions to fruition.

Conclusion:

In conclusion, Gary J Nabel stands as a beacon of innovation in the field of vaccines and protein technology. His patents reflect a commitment to excellence, and his collaborations have enriched the scientific community. Nabel's contributions have not only shaped the landscape of preventative medicine but also paved the way for future advancements in the field.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…